BioStem Technologies Secures Four New U.S. Design Patents for Fenestrated Placental Allograft Innovations

BioStem Technologies, Inc. (OTCID:BSEM), a leader in regenerative medicine focused on perinatal tissue allograft products, has announced that the United States Patent and Trademark Office (USPTO) has issued four new U.S. design patents covering its proprietary fenestrated human placental allograft technologies. This development marks a significant expansion of BioStem’s intellectual property portfolio, reinforcing the company’s position in advanced allograft innovation.

The newly granted patents protect fenestrated placental allograft designs engineered to enhance conformability, fluid transfer, and handling during clinical use. These designs are intended for surgical and wound care applications where improved drainage, flexibility, and tissue integration can optimize placement and promote better healing outcomes.

Specifically, the patents cover fenestrated allograft designs that facilitate effective fluid management, a critical factor in surgical and wound care environments. The designs preserve the structural integrity of amniotic and chorion tissues while supporting moisture control in complex wound settings.

One patent focuses on fenestrated allografts that enable controlled fluid passage to support wound drainage and overall wound management across a variety of clinical applications. Collectively, these innovations aim to improve the performance and therapeutic benefits of placental-derived allografts.

Jason Matuszewski, Chairman and CEO of BioStem Technologies, emphasized the strategic importance of these patents, stating, "These newly issued patents represent another important step in strengthening the intellectual property foundation supporting our placental-derived allograft technologies. Protecting the innovations behind our products helps support our long-term growth strategy while reinforcing our commitment to advancing regenerative medicine through differentiated technologies designed to improve patient care."

BioStem’s intellectual property portfolio now includes more than 100 patents and patent applications worldwide. The company continues to invest in innovation across placental tissue processing, preservation technologies, and allograft designs to develop next-generation products for wound care and surgical use.

The company’s proprietary processing technologies—BioRetain®, CryoTek®, and SteriTek®—are designed to optimize preservation of the natural structural and biological characteristics of placental tissues. This preservation supports their effective use in a broad range of clinical procedures.

BioStem Technologies is publicly traded and recognized for its biomedical innovation in developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. Its products are utilized by clinicians across multiple specialties, supported by ongoing clinical research and a national commercial footprint.

The company’s quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (AATB). These systems comply with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP). BioStem’s portfolio includes well-known brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™.

For further information or to follow BioStem’s latest developments, interested parties can visit the company’s website or connect via social media platforms including X, LinkedIn, and Facebook.